Physician profile
John M Sloan
NPI 1659345320
$256,514.23
in general payments reported to CMS, 2019-2025
23 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $74K · 2021: $36K · 2022: $62K · 2023: $27K · 2024: $18K · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Travel and Lodging: $2,749 · Food and Beverage: $2,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,028.87 |
| Travel and Lodging | $2,748.72 |
| Food and Beverage | $2,087.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $181,970.10 | 2019-2025 | Orserdu |
| Adc Therapeutics America, INC. | $13,326.02 | 2024-2025 | |
| Emd Serono, INC. | $10,700.00 | 2019-2020 | |
| Kite Pharma, INC. | $8,784.54 | 2020-2022 | |
| Acrotech Biopharma INC. | $8,571.37 | 2023 | Beleodaq |
| Servier Pharmaceuticals LLC | $7,192.30 | 2023 | |
| Seagen INC. | $5,452.75 | 2021-2023 | Adcetris |
| Astrazeneca Pharmaceuticals Lp | $5,107.75 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $4,152.16 | 2021 | |
| Bioverativ Therapeutics INC. | $3,637.08 | 2019 | |
| Invivyd INC | $2,625.00 | 2024 | Pemgarda |
| Novartis Pharmaceuticals Corporation | $2,362.50 | 2024 | |
| Janssen Biotech, INC. | $1,345.34 | 2025 | Tecvayli, Darzalex, Carvykti |
| Kyowa Kirin, INC. | $374.34 | 2024-2025 | Poteligeo |
| Genzyme Corporation | $275.25 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $125.83 | 2023-2024 | Venclexta |
| Amgen INC. | $122.15 | 2021 | |
| Epizyme, INC. | $120.83 | 2022 | |
| Pfizer INC. | $101.56 | 2022 | |
| Daiichi Sankyo INC. | $93.94 | 2025 | |
| Rigel Pharmaceuticals, INC. | $52.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.55 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sloan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.